Goldman Sachs Sticks to Its Buy Rating for Smith & Nephew (SN)

Goldman Sachs analyst Richard Felton maintained a Buy rating on Smith & Nephew today and set a price target of p1,650.00.

Claim 50% Off TipRanks Premium and Invest with Confidence

• Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential

Felton covers the Healthcare sector, focusing on stocks such as Smith & Nephew, ConvaTec, and Argenx Se. According to TipRanks, Felton has an average return of 7.1% and a 53.98% success rate on recommended stocks.

In addition to Goldman Sachs, Smith & Nephew also received a Buy from Citi’s Veronika Dubajova in a report issued today. However, on the same day, Barclays maintained a Hold rating on Smith & Nephew (LSE: SN).

Based on Smith & Nephew’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p2.99 billion and a net profit of p295.65 million. In comparison, last year the company earned a revenue of p2.83 billion and had a net profit of p214 million

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SN in relation to earlier this year.